PRESS RELEASES

Date Title and Summary View
Toggle Summary GlycoMimetics Appoints Scott Koenig of MacroGenics to Board of Directors
Two Long-Time Board Members to Step Down After Company's 2017 Annual Meeting ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Scott Koenig , M.D., Ph.D., to its Board of Directors. Dr. Koenig is President and Chief Executive Officer and a
View HTML
Toggle Summary GlycoMimetics Completes Enrollment of Newly Diagnosed AML Patient Cohort in Phase 2 Clinical Trial of GMI-1271
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that the first of two patient cohorts in its Phase 2 acute myeloid leukemia (AML) trial of GMI-1271 has completed enrollment. This cohort is comprised of 25 patients 60 years of age or older with newly diagnosed
View HTML
Toggle Summary GlycoMimetics to Present New Preclinical Data in Multiple Myeloma at AACR Annual Meeting 2017
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that pre-clinical research demonstrating the potential of two of its drug candidates, GMI-1271 and GMI-1359, against multiple myeloma will be shared via an oral presentation at the American Association for Cancer
View HTML
Toggle Summary GlycoMimetics Reports Fourth Quarter and Year-End 2016 Results
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today reported progress on its clinical development programs and its financial results for the fourth quarter and year ended December 31, 2016 . "In 2016, GlycoMimetics made significant progress across its clinical pipeline,
View HTML
Toggle Summary GlycoMimetics to Present at Cowen 37th Annual Health Care Conference
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Cowen 37th Annual Health Care Conference in Boston , on Tuesday, March 7, 2017 , at 10:40 a.m. ET .
View HTML
Toggle Summary GlycoMimetics' GMI-1271 Continues to Yield High Remission Rates, Favorable Tolerability in Two Phase 2 Arms of Ongoing Phase 1/2 Clinical Trial for AML
Results to be presented today in poster at 58 th American Society of Hematology (ASH) Annual Meeting and Expo ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. ( NASDAQ : GLYC) today announced that results of its Phase 1/2 clinical trial on its lead drug candidate GMI-1271 continued to show
View HTML
Toggle Summary GlycoMimetics to Present at Upcoming Healthcare Investor Conferences
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. ( NASDAQ : GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at two healthcare investor conferences next week, as follows: STIFEL 2016 HEALTHCARE CONFERENCE WHEN: NOVEMBER 15, 2016 AT 4:30 PM ET
View HTML
Toggle Summary GlycoMimetics to Present Preclinical Cancer Results at Society for Immunotherapy of Cancer Meeting
- Data illustrate potential for synergy between drug candidate GMI-1359 and PD-L1 antagonists when used in combination to treat solid tumors ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. ( NASDAQ : GLYC) today announced that data showing enhanced effectiveness of an antibody antagonist to
View HTML
Toggle Summary GlycoMimetics Reports Third Quarter 2016 Results and Progress in Clinical Development
ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. ( NASDAQ : GLYC) today reported progress on its clinical development programs and its financial results for the quarter ended September 30, 2016 . "For GlycoMimetics, the third quarter was highlighted by continued achievements in our clinical
View HTML
Toggle Summary Data from Three GlycoMimetics Drug Candidates to Be Highlighted at 58th Annual American Society of Hematology (ASH) Meeting
Oral presentation and six posters illustrate advancement of GlycoMimetics' pipeline Poster presentation will update clinical data from on-going AML study of GMI-1271 ROCKVILLE, Md. --(BUSINESS WIRE)-- GlycoMimetics, Inc. ( NASDAQ : GLYC) today announced that data from three drug candidates in its
View HTML